Axsome Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering novel therapies for central nervous system (CNS) disorders. The company's commercial portfolio features three key marketed products: Auvelity (dextromethorphan-bupropion) for major depressive disorder and agitation associated with Alzheimer's disease dementia; Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea; and Symbravo (meloxicam-rizatriptan) for the acute treatment of migraine. Axsome is actively advancing a robust late-stage pipeline targeting multiple high-unmet-need psychiatric and neurological conditions.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the AUVELITY sales force to approximately 600 sales representatives to support strong demand in Major Depressive Disorder (MDD) and prepare for the commercial launch in Alzheimer's disease agitation.
Expected impact: Aims to maximize market penetration and support the peak sales potential of AUVELITY.
Expanding the SYMBRAVO sales force from 100 to 150 representatives to support growing demand and expanded commercial payer coverage.
Expected impact: Aims to accelerate prescription growth and capture market share in the headache/migraine space.
Advancing multiple late-stage clinical programs, including AXS-12 in narcolepsy, AXS-14 in fibromyalgia (FORWARD study), and multiple Phase 3 trials for solriamfetol.
Expected impact: Aims to secure up to seven potential product approvals through 2028 to diversify the CNS portfolio.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Avenue Therapeutics' subsidiary Baergic Bio to obtain exclusive global rights to BAER-101 (now AXS-17), a Phase 2-ready oral GABAA receptor positive allosteric modulator for epilepsy.
Financial impact: Upfront payment of $0.3 million, with potential development and regulatory milestones of up to $2.5 million for the first indication, $1.5 million for subsequent indications, and up to $79 million in sales-based milestones plus royalties.
Strategic Partnerships
Obtained exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor, to develop for schizophrenia and Tourette syndrome.
Terms: Undisclosed upfront payment; Takeda is eligible to receive development, regulatory, and commercial milestone payments, as well as royalties on potential global net sales.